Early Remdesivir to Prevent Progression to Severe Covid 19 in Outpatients

Submitted by vgreene on Thu, 01/06/2022 - 19:34
Exclude Patient Type Detail Header
No
Detail Type
Text
Detail Text
KEY FINDINGS in outpts at high risk for dz progression 3 day RDV course resulted in 87 lower hospitalization or death risk vs placebo
Study considerations double blind RCT study stopped early due to administrative reasons some subpopulations not adequately included primarily adult pts excluded vaccinated pts trial conducted before variants emergence
Access N Engl J Med article
Patient Type Detail Header (Long)
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients